Synthesis and structure-activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists

被引：41

作者：

Han, XJ ^{[1
]}

Pin, SS ^{[1
]}

Burris, K ^{[1
]}

Fung, LK ^{[1
]}

Huang, S ^{[1
]}

Taber, MT ^{[1
]}

Zhang, J ^{[1
]}

Dubowchik, GM ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2005年 / 15卷 / 18期

关键词：

corticotropin-releasing factor 1; antagonists; SAR; pharmacokinetic properties;

D O I：

10.1016/j.bmcl.2005.06.028

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

8-Aryl-1,3a,8-triaza-cyclopenta[a]indenes represent a novel series of high binding affinity corticotropin-releasing factor 1 receptor antagonists. Here, we report their synthesis, SAR, and pharmacokinetic properties of compound 8e (K-i = 23 nM). (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：4029 / 4032

页数：4

共 20 条

[1] Anisimova VA, 1999, PHARM CHEM J, V33, P361, DOI DOI 10.1007/BF02508707
[2] Nonpeptide corticotropin releasing hormone type 1 receptor antagonists as medications, and imaging agents
Contoreggi, C
Ayala, A
Grant, S
Eckelman, W
Webster, E
Rice, K
[J]. DRUGS OF THE FUTURE, 2002, 27 (11) : 1093 - 1100
[3] Functional corticotropin-releasing factor receptors in human neuroblastoma cells
Dieterich, KD
DeSouza, EB
[J]. BRAIN RESEARCH, 1996, 733 (01) : 113 - 118
[4] Novel approaches to the treatment of depression by modulating the hypothalamic-pituitary-adrenal axis
Dinan, TG
[J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2001, 16 (01) : 89 - 93
[5] 2-arylaminothiazoles as high-affinity corticotropin-releasing factor 1 receptor (CRF1R) antagonists:: Synthesis, binding studies and behavioral efficacy
Dubowchik, GM
Michne, JA
Zuev, D
Schwartz, W
Scola, PM
James, CA
Ruediger, EH
Pin, SS
Burris, KD
Balanda, LA
Gao, Q
Wu, DD
Fung, L
Fiedler, T
Browman, KE
Taber, MT
Zhang, J
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (22) : 3997 - 4000
[6] Corticotropin releasing factor (CRF) receptor modulators: Progress and opportunities for new therapeutic agents
Gilligan, PJ
Robertson, DW
Zaczek, R
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (09) : 1641 - 1660
[7] Grigoriadis Dimitri E., 2001, Current Medicinal Chemistry - Central Nervous System Agents, V1, P63, DOI 10.2174/1568015013358734
[8] Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists
Han, XJ
Michne, JA
Pin, SS
Burris, KD
Balanda, LA
Fung, LK
Fiedler, T
Browman, KE
Taber, MT
Zhang, J
Dubowchik, GM
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (17) : 3870 - 3873
[9] A short catalytic enantioselective synthesis of the proinflammatory eicosanoid 12(R)-hydroxy-5(Z),8(Z),10(E),14(Z)-eicosatetraenoic acid (12(R)-HETE)
Han, XJ
Corey, EJ
[J]. ORGANIC LETTERS, 2000, 2 (16) : 2543 - 2544
[10] International union of pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands
Hauger, RL
Grigoriadis, DE
Dallman, MF
Plotsky, PM
Vale, WW
Dautzenberg, FM
[J]. PHARMACOLOGICAL REVIEWS, 2003, 55 (01) : 21 - 26

← 1 2 →